查看購物車
  • English
  • Japanese
全球生物製藥CDMO市場：按規模、細胞類型、分子類型、適應症、服務和地區分類的分析和預測（2025-2035年）
市場調查報告書
商品編碼
1982257

全球生物製藥CDMO市場：按規模、細胞類型、分子類型、適應症、服務和地區分類的分析和預測（2025-2035年）

Biologics CDMO Market - A Global and Regional Analysis: Focus on Scale, Cell Type, Molecule Type, Indication, Services, and Region - Analysis and Forecast, 2025-2035
出版日期: | 出版商: BIS Research | 英文 214 Pages | 商品交期: 1-5個工作天內

價格

全球生物製藥CDMO市場：產業概覽

全球生物製藥 CDMO 市場預計將從 2024 年的 271.9 億美元成長到 2035 年的 1,053.6 億美元，預計在 2025 年至 2035 年的預測期內，複合年成長率將達到 13.59%。

隨著全球生物製藥產業日益依賴契約製造生產商來支持複雜生物製藥的研發、生產和商業化，生物製藥CDMO市場正經歷持續成長。這一擴張是由對生物製藥（包括單株抗體、重組蛋白和疫苗）日益成長的需求所驅動的。透過將生物製藥研發和生產的關鍵階段外包，製藥公司可以降低成本、規避風險，並專注於其核心競爭力。

關鍵市場統計數據
預測期 2025-2035
2025 年評估 294.6億美元
2035年預測 1053.6億美元
複合年成長率 13.59%

受生物製藥產業多個關鍵因素的推動，生物製藥合約研發生產機構（CDMO）市場正經歷顯著成長。隨著全球對包括單株抗體（mAb）、疫苗、重組蛋白和基因療法在內的生物製藥產品的需求持續上升，對專業製造外包機構的需求也日益凸顯。

從生產規模來看，商業化環節佔主導。這是因為隨著生物製藥產品核准上市數量的增加，企業正從早期臨床生產轉向大規模生產。隨著生物製藥產品從研發階段邁向大規模商業化生產，對外部生產服務的需求顯著成長。這一環節對合約研發生產機構（CDMO）至關重要，因為它反映了為滿足全球醫藥市場需求而將大規模生產外包的趨勢日益成長。

就細胞類型而言，哺乳動物表現系統優於微生物和其他平台，因為它們最適合現代生物製藥的結構和功能複雜性。哺乳動物系統，特別是基於CHO細胞的平台，對於生產單株抗體、雙特異性抗體和含Fc片段的融合蛋白至關重要，這些蛋白需要進行類似人類的轉譯後修飾，尤其是糖基化，以確保其有效性和安全性。

就適應症而言，腫瘤學是推動市場發展的主要動力。全球癌症發生率的上升以及人們對新型生物製藥療法（例如免疫療法）研發日益成長的興趣，正在推動該領域對合約研發生產（CDMO）服務的需求。自體免疫疾病、感染疾病和神經系統疾病也是生物製藥CDMO市場的重要適應症，但腫瘤學仍佔最大佔有率。

按分子類型分類，單株抗體（mAb）佔據最大佔有率。單株抗體一直是生物製藥療法的基礎，尤其是在腫瘤、自體免疫疾病和其他治療領域。由於其廣泛的臨床成功和高市場價值，單株抗體在生物製藥生產中佔據主導地位。其他生物製藥產品，例如重組蛋白和疫苗，也對市場成長有所貢獻，但在外包需求方面，它們僅次於單株抗體。

從區域來看，北美仍然是領先的市場，這得益於其大型製藥企業、活躍的研發活動以及美國食品藥物管理局（FDA）等監管機構的存在。歐洲在生物製藥製造領域也扮演著重要角色，歐洲藥品管理局（EMA）則監管著一個蓬勃發展的藥品市場。亞太地區是成長最快的地區，中國和印度等國家正在不斷擴大其生物製藥製造能力。亞太地區的生產成本效益高，且醫療保健基礎設施不斷完善，使其成為尋求生物製藥生產外包的本地和全球製藥公司的理想市場。拉丁美洲和中東及非洲是新興市場，醫療保健和製藥領域的投資不斷增加，推動了生物製藥製造的成長，儘管其市場佔有率仍小於北美和亞太地區。

本報告檢視了全球生物製藥 CDMO 市場，總結了關鍵趨勢、市場影響因素、法律制度、市場規模趨勢和預測、按各個細分市場和主要國家/地區進行的詳細分析、競爭格局以及主要企業的概況。

目錄

執行摘要

範圍和定義

第1章：全球生物製藥CDMO市場：產業展望

  • 市場概覽
    • 全球生物製藥CDMO市場規模：趨勢與預測
  • 主要市場趨勢
    • 從大型單株抗體轉向聯合治療方法（抗體藥物複合體、雙特異性抗體、細胞和基因療法）
    • 在商業生產上採用一次性、連續式和灌注式生物程序
  • CDMO在生物製藥生產中的作用
  • 專利分析
    • 專利申請趨勢（按國家/地區分類）
    • 專利申請數量趨勢（按年份）
  • 監理情勢
  • 市場動態
    • 市場促進因素
    • 市場挑戰
    • 市場機遇

第2章：全球生物製藥CDMO市場（依規模）

  • 臨床前和臨床
  • 商業化

第3章：全球生物製藥CDMO市場（依細胞類型分類）

  • 哺乳動物
  • 微生物
  • 其他

第4章：全球生物製藥CDMO市場（依適應症分類）

  • 瘤
  • 自體免疫疾病
  • 感染疾病
  • 神經
  • 其他

第5章：全球生物製藥CDMO市場（依分子類型分類）

  • 單株抗體
  • 重組蛋白
  • 疫苗
  • 荷爾蒙
  • 其他

第6章：全球生物製藥CDMO市場（依服務分類）

  • 細胞株構建
  • 分析與配方開發
  • 製程開發
  • cGMP生產
  • 灌裝、精加工、包裝
  • 其他

第7章：全球生物製藥CDMO市場（按地區分類）

  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東和非洲
    • 區域概覽
    • 市場成長促進因素
    • 市場挑戰
    • 市場規模及預測

第8章：競爭標竿分析與公司概況

  • 關鍵策略及發展現狀：依公司分類
    • 資金籌措活動
    • M&A
    • 監管核准和產品上市
    • 夥伴關係、合作與業務拓展
    • 企業定位/企業市場占有率分析
  • 公司簡介
    • AbbVie, Inc.
    • Wuxi Biologics
    • Pfizer, Inc.
    • Merck KGaA
    • Catalent, Inc.
    • Charles River Laboratories
    • GenScript Biotech Corporation
    • Lonza Group
    • Samsung Biologics
    • AGC Biologics
    • Parexel International (MA) Corporation
    • Boehringer Ingelheim International GmbH
    • Thermo Fisher Scientific, Inc.
    • Avid Bioservices, Inc.
    • Novartis AG
    • 新興企業名單

第9章：調查方法

Product Code: BHL1501SB

This report can be delivered within 1 working day.

Global Biologics CDMO market: Industry Overview

The global biologics CDMO market is projected to reach $105.36 billion by 2035 from $27.19 billion in 2024, growing at a CAGR of 13.59% during the forecast period 2025-2035. The biologics CDMO market has been experiencing sustained growth as the global biopharmaceutical industry increasingly relies on contract manufacturers to support the development, production, and commercialization of complex biologics. This expansion is driven by the rising demand for biologic therapies, which include monoclonal antibodies, recombinant proteins, and vaccines. By outsourcing critical stages of biologics development and manufacturing, pharmaceutical companies are able to reduce costs, mitigate risks, and focus on their core competencies.

KEY MARKET STATISTICS
Forecast Period2025 - 2035
2025 Evaluation$29.46 Billion
2035 Forecast$105.36 Billion
CAGR13.59%

The biologics CDMO market is experiencing significant growth, driven by several key factors within the broader biopharmaceutical landscape. As the global demand for biologic therapies including monoclonal antibodies (mAbs), vaccines, recombinant proteins, and gene therapies continues to rise, the need for outsourcing manufacturing to specialized CDMOs is becoming more pronounced.

Global Biologics CDMO Market Lifecycle Stage

In the biologics CDMO market, the lifecycle stage of a molecule strongly determines both sponsor expectations and the type of CDMO that is most competitive. During preclinical and early clinical stages, sponsors prioritize speed, scientific flexibility, and development depth, favouring CDMOs with strong cell line development, process and analytical development, and small-scale GMP capabilities that can move material to the clinic quickly. As programs advance into mid-stage clinical development, the focus shifts toward process robustness, comparability, and tighter control strategies, making CDMOs with disciplined process characterization, scalable platforms, and mature change management more attractive. By late-stage clinical development and commercial launch, competition centers on execution excellence rather than innovation, with sponsors selecting CDMOs that demonstrate regulatory credibility, consistent batch success, validated processes, and secure capacity supported by multi-site redundancy. In the post-approval phase, lifecycle management becomes the differentiator, as CDMOs that can efficiently handle scale expansions, post-approval changes, cost-reduction initiatives, and new presentations are more likely to retain long-term contracts. Across the lifecycle, CDMO selection resembles a relay race, where early speed gets the molecule moving, but disciplined handoffs and reliable execution are what ultimately carry it across the commercial finish line.

Market Segmentation:

Segmentation 1 - By Scale

  • Preclinical and Clinical
  • Commercial

Based on Scale, the commercial segment dominates the biologics CDMO market, with companies shifting from early?stage clinical production to large?scale manufacturing due to the increasing approval and market entry of biologic therapies. As biologics move from the development phase to large?scale commercial production, the demand for external manufacturing services grows significantly. This segment is crucial for CDMOs as it reflects the growing trend of outsourcing full?scale production to meet the demands of the global pharmaceutical market.

Segmentation 2 - By Cell Type

  • Mammalian
  • Microbial
  • Others

Mammalian expression systems dominate over microbial and other platforms because they are best suited for the structural and functional complexity of modern biologics. Mammalian systems, particularly CHO-based platforms, are essential for producing monoclonal antibodies, bispecifics, and Fc-containing fusion proteins that require human-like post-translational modifications, especially glycosylation, to ensure efficacy and safety.

Segmentation 3 - By Indication

  • Oncology
  • Autoimmune Diseases
  • Infectious Diseases
  • Neurology
  • Others

In terms of indications, oncology leads the biologics CDMO market. The rising incidence of cancer globally and the increased focus on developing novel biologic therapies, such as immune-oncology treatments, drive the demand for CDMO services in this field. Autoimmune diseases, infectious diseases, and neurological disorders also represent important disease indication under biologics CDMO market, but oncology maintains the largest share.

Segmentation 4 - By Molecule Type

  • Monoclonal Antibodies
  • Recombinant Protein
  • Vaccines
  • Hormones
  • Others

Among the various biologic molecule types, monoclonal antibodies (mAbs) hold the largest share in the biologics CDMO market. mAbs continue to be the cornerstone of biologic therapies, particularly in oncology, autoimmune diseases, and other therapeutic areas. Their widespread clinical success and high market value make them a dominant force in biologic manufacturing. Other biologic types, such as recombinant proteins and vaccines, contribute to market growth but are secondary to mAbs in terms of outsourcing demand.

Segmentation 5 - By Services

  • Cell Line Development
  • Analytical and Formulation Development
  • Process Development
  • cGMP Manufacturing
  • Fill Finish and Packaging
  • Other Services

In terms of service offerings, cGMP manufacturing services are the most significant in the biologics CDMO market. These services include large?scale production, fill?finish operations, and packaging, which are essential for ensuring that biologics meet regulatory standards and are available to the market. CDMOs are increasingly providing integrated services that encompass the entire biologics lifecycle, from drug development and formulation to commercial production. Analytical services and regulatory support are also crucial services but are secondary to manufacturing.

Segmentation 6 - By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

Regionally, North America remains the dominant market for biologics CDMO, driven by the presence of large pharmaceutical companies, high levels of R&D activity, and regulatory bodies like the FDA. The Europe region also plays a significant role in biologics manufacturing, with the EMA overseeing a robust pharmaceutical market. In contrast, Asia-Pacific is the fastest-growing region, with countries like China and India expanding their capabilities in biologics manufacturing. The cost?effectiveness of production in Asia-Pacific, coupled with expanding healthcare infrastructure, makes it an attractive region for both local and global pharmaceutical companies looking to outsource biologics production. Latin America and Middle East and Africa represent emerging markets, with increasing investment in the healthcare and pharmaceutical sectors driving growth in biologics manufacturing, though their market share remains smaller compared to North America and Asia-Pacific.

Demand - Drivers and Limitations

Demand drivers for the global Biologics CDMO market:

  • Rising Prevalence of Chronic and Rare Diseases Driving Demand for Biologics CDMO Services
  • Strong Investment and R&D Funding Leading to Increased Demand for Biologics

Limitations for the global Biologics CDMO market:

  • Limited Small-Batch and Sterile Biomanufacturing Capacity for Complex Biologics
  • Operational Challenges in Technology Transfer and Scaling Up for Biologics Manufacturing

How can this report add value to an organization?

Product/Innovation: This report enables organizations to identify high-value opportunities in global Biologics CDMO market, including innovation in the biologics CDMO market is showing up less as "new products on shelves" and more as new manufacturing platforms and service packages that shorten timelines, raise yields, and reduce regulatory risk. The biggest product shift is the maturation of single-use and intensified manufacturing. A second innovation wave is in analytics, automation, and fill/finish formats-where differentiation is increasingly about control and contamination prevention. On analytics, CDMOs are adopting advanced methods.

Growth/Marketing: The report delivers in-depth insights into regional adoption trends, emerging markets, and partnership opportunities, supporting strategic market entry and commercialization planning. It enables companies to identify growth potential across scale, cell type, molecule type indication, services segments. By understanding regional R&D investments, regulatory frameworks, and technology adoption rates, organizations can refine marketing, licensing, and collaboration strategies, maximize visibility, and increase return on investment in a competitive global landscape.

Competitive: This report provides comprehensive company profiling, competitive benchmarking, highlighting strategic collaborations, funding activities, mergers, acquisitions, and technology adoption trends. Stakeholders gain a clear understanding of competitor focus areas, R&D priorities, and market positioning. This intelligence allows organizations to identify gaps, anticipate market shifts, and formulate strategies to differentiate themselves, optimize market entry, and maintain leadership in the AI-driven antibody discovery ecosystem.

Key Market Players and Competitive Landscape

The global Biologics CDMO market is characterized by a highly competitive and evolving landscape, with participation from innovative biotechnology startups, established pharmaceutical companies, and biologic CDMO service providers. Key players include:

  • Lonza
  • Catalent, Inc.
  • Samsung Biologics
  • Thermo Fisher Scientific, Inc.
  • Wuxi Biologics
  • Boehringer Ingelheim GmbH
  • Charles River Laboratories

The competitive landscape of the biologics CDMO market is characterized by a mix of large multinational players and regional specialists, each offering a wide range of services from early-stage development to large-scale commercial manufacturing. Leading global companies such as Lonza Group, Thermo Fisher Scientific, Inc. (Patheon Services), and WuXi Biologics dominate the market due to their extensive capabilities, advanced manufacturing facilities, and strong reputations for quality and reliability. These companies leverage their global reach, state-of-the-art technology, and multi-platform production capabilities, such as mammalian, microbial, and cell-free systems, to cater to the increasing demand for complex biologic therapies, particularly monoclonal antibodies and biosimilars.

Table of Contents

Executive Summary

Scope and Definition

1 Global Biologics CDMO Market: Industry Outlook

  • 1.1 Market Overview
    • 1.1.1 Global Biologics CDMO Market, $Million, 2024-2035
  • 1.2 Key Market Trends
    • 1.2.1 Shift from Blockbuster mAbs to Complex Modalities (ADCs, Bispecifics, Cell and Gene Therapies)
    • 1.2.2 Adoption of Single-Use, Continuous, and Perfusion Bioprocessing in Commercial Manufacturing
  • 1.3 Role of CDMOs in Biologics Manufacturing
  • 1.4 Patent Analysis
    • 1.4.1 Patent Filing Trend (by Country)
    • 1.4.2 Patent Filing Trend (by Year)
  • 1.5 Regulatory Landscape
  • 1.6 Market Dynamics
    • 1.6.1 Market Drivers
      • 1.6.1.1 Rising Prevalence of Chronic and Rare Diseases Driving Demand for Biologics CDMO Services
      • 1.6.1.2 Strong Investment and R&D Funding Leading to Increased Demand for Biologics
      • 1.6.1.3 Increasing Partnerships and Collaborations in the Biologics CDMO Business
    • 1.6.2 Market Challenges
      • 1.6.2.1 Limited Small-Batch and Sterile Biomanufacturing Capacity for Complex Biologics
      • 1.6.2.2 Operational Challenges in Technology Transfer and Scaling Up for Biologics Manufacturing
      • 1.6.2.3 Shortage of Skilled Professionals
    • 1.6.3 Market Opportunities
      • 1.6.3.1 Advent of Personalized Medicine and Small-Batch Biologics Production

2 Global Biologics CDMO Market (by Scale), ($Million), 2024-2035

  • 2.1 Pre-Clinical and Clinical
  • 2.2 Commercial

3 Global Biologics CDMO Market (by Cell Type), ($Million), 2024-2035

  • 3.1 Mammalian
  • 3.2 Microbial
  • 3.3 Others

4 Global Biologics CDMO Market (by Indication), ($Million), 2024-2035

  • 4.1 Oncology
  • 4.2 Autoimmune Diseases
  • 4.3 Infectious Diseases
  • 4.4 Neurology
  • 4.5 Others

5 Global Biologics CDMO Market (by Molecule Type), ($Million), 2024-2035

  • 5.1 Monoclonal Antibodies
  • 5.2 Recombinant Proteins
  • 5.3 Vaccines
  • 5.4 Hormones
  • 5.5 Others

6 Global Biologics CDMO Market (by Services), ($Million), 2024-2035

  • 6.1 Cell Line Development
  • 6.2 Analytical and Formulation Development
  • 6.3 Process Development
  • 6.4 cGMP Manufacturing
  • 6.5 Fill Finish and Packaging
  • 6.6 Other Services

7 Global Biologics CDMO Market (by Region), ($Million), 2024-2035

  • 7.1 North America
    • 7.1.1 Regional Overview
    • 7.1.2 Driving Factors for Market Growth
    • 7.1.3 Factors Challenging the Market
    • 7.1.4 Market Sizing and Forecast
      • 7.1.4.1 North America Biologics CDMO Market, by Cell Type
      • 7.1.4.2 North America Biologics CDMO Market, by Molecule Type
      • 7.1.4.3 North America Biologics CDMO Market, by Scale
      • 7.1.4.4 North America Biologics CDMO Market, by Country
        • 7.1.4.4.1 U.S.
        • 7.1.4.4.2 Canada
  • 7.2 Europe
    • 7.2.1 Regional Overview
    • 7.2.2 Driving Factors for Market Growth
    • 7.2.3 Factors Challenging the Market
    • 7.2.4 Market Sizing and Forecast
      • 7.2.4.1 Europe Biologics CDMO Market, by Cell Type
      • 7.2.4.2 Europe Biologics CDMO Market, by Molecule Type
      • 7.2.4.3 Europe Biologics CDMO Market, by Scale
      • 7.2.4.4 Europe Biologics CDMO Market, by Country
        • 7.2.4.4.1 Germany
        • 7.2.4.4.2 U.K.
        • 7.2.4.4.3 France
        • 7.2.4.4.4 Italy
        • 7.2.4.4.5 Spain
        • 7.2.4.4.6 Rest-of-Europe
  • 7.3 Asia-Pacific
    • 7.3.1 Regional Overview
    • 7.3.2 Driving Factors for Market Growth
    • 7.3.3 Factors Challenging the Market
    • 7.3.4 Market Sizing and Forecast
      • 7.3.4.1 Asia-Pacific Biologics CDMO Market, by Cell Type
      • 7.3.4.2 Asia-Pacific Biologics CDMO Market, by Molecule Type
      • 7.3.4.3 Asia-Pacific Biologics CDMO Market, by Scale
      • 7.3.4.4 Asia-Pacific Biologics CDMO Market, by Country
        • 7.3.4.4.1 China
        • 7.3.4.4.2 Japan
        • 7.3.4.4.3 India
        • 7.3.4.4.4 South Korea
        • 7.3.4.4.5 Australia
        • 7.3.4.4.6 Rest-of-Asia-Pacific
  • 7.4 Latin America
    • 7.4.1 Regional Overview
    • 7.4.2 Driving Factors for Market Growth
    • 7.4.3 Factors Challenging the Market
    • 7.4.4 Market Sizing and Forecast
      • 7.4.4.1 Latin America Biologics CDMO Market, by Cell Type
      • 7.4.4.2 Latin America Biologics CDMO Market, by Molecule Type
      • 7.4.4.3 Latin America Biologics CDMO Market, by Scale
      • 7.4.4.4 Latin America Biologics CDMO Market, by Country
        • 7.4.4.4.1 Brazil
        • 7.4.4.4.2 Mexico
        • 7.4.4.4.3 Rest-of-Latin America
  • 7.5 Middle East and Africa
    • 7.5.1 Regional Overview
    • 7.5.2 Driving Factors for Market Growth
    • 7.5.3 Factors Challenging the Market
    • 7.5.4 Market Sizing and Forecast
      • 7.5.4.1 Middle East and Africa Biologics CDMO Market, by Cell Type
      • 7.5.4.2 Middle East and Africa Biologics CDMO Market, by Molecule Type
      • 7.5.4.3 Middle East and Africa Biologics CDMO Market, by Scale
      • 7.5.4.4 Middle East and Africa Biologics CDMO Market, by Country
        • 7.5.4.4.1 K.S.A
        • 7.5.4.4.2 UAE
        • 7.5.4.4.3 Rest-of-Middle East and Africa

8 Competitive Benchmarking and Company Profiles

  • 8.1 Key Strategies and Developments by Company
    • 8.1.1 Funding Activities
    • 8.1.2 Mergers and Acquisitions
    • 8.1.3 Regulatory Approvals and Product Launches
    • 8.1.4 Partnerships, Collaborations, and Business Expansions
    • 8.1.5 Company Positioning/Company Share Analysis (2023 and 2024)
  • 8.2 Company Profiles
    • 8.2.1 AbbVie, Inc.
      • 8.2.1.1 Overview
      • 8.2.1.2 Top Products/Service Portfolio
      • 8.2.1.3 Top Competitors
      • 8.2.1.4 Target Customers
      • 8.2.1.5 Key Personal
      • 8.2.1.6 Analyst View
    • 8.2.2 Wuxi Biologics
      • 8.2.2.1 Overview
      • 8.2.2.2 Top Products/Service Portfolio
      • 8.2.2.3 Top Competitors
      • 8.2.2.4 Target Customers
      • 8.2.2.5 Key Personal
      • 8.2.2.6 Analyst View
    • 8.2.3 Pfizer, Inc.
      • 8.2.3.1 Overview
      • 8.2.3.2 Top Products/Service Portfolio
      • 8.2.3.3 Top Competitors
      • 8.2.3.4 Target Customers
      • 8.2.3.5 Key Personal
      • 8.2.3.6 Analyst View
    • 8.2.4 Merck KGaA
      • 8.2.4.1 Overview
      • 8.2.4.2 Top Products/Service Portfolio
      • 8.2.4.3 Top Competitors
      • 8.2.4.4 Target Customers
      • 8.2.4.5 Key Personal
      • 8.2.4.6 Analyst View
    • 8.2.5 Catalent, Inc.
      • 8.2.5.1 Overview
      • 8.2.5.2 Top Products/Service Portfolio
      • 8.2.5.3 Top Competitors
      • 8.2.5.4 Target Customers
      • 8.2.5.5 Key Personal
      • 8.2.5.6 Analyst View
    • 8.2.6 Charles River Laboratories
      • 8.2.6.1 Overview
      • 8.2.6.2 Top Products/Service Portfolio
      • 8.2.6.3 Top Competitors
      • 8.2.6.4 Target Customers
      • 8.2.6.5 Key Personal
      • 8.2.6.6 Analyst View
    • 8.2.7 GenScript Biotech Corporation
      • 8.2.7.1 Overview
      • 8.2.7.2 Top Products/Service Portfolio
      • 8.2.7.3 Top Competitors
      • 8.2.7.4 Target Customers
      • 8.2.7.5 Key Personal
      • 8.2.7.6 Analyst View
    • 8.2.8 Lonza Group
      • 8.2.8.1 Overview
      • 8.2.8.2 Top Products/Service Portfolio
      • 8.2.8.3 Top Competitors
      • 8.2.8.4 Target Customers
      • 8.2.8.5 Key Personal
      • 8.2.8.6 Analyst View
    • 8.2.9 Samsung Biologics
      • 8.2.9.1 Overview
      • 8.2.9.2 Top Products/Service Portfolio
      • 8.2.9.3 Top Competitors
      • 8.2.9.4 Target Customers
      • 8.2.9.5 Key Personal
      • 8.2.9.6 Analyst View
    • 8.2.10 AGC Biologics
      • 8.2.10.1 Overview
      • 8.2.10.2 Top Products/Service Portfolio
      • 8.2.10.3 Top Competitors
      • 8.2.10.4 Target Customers
      • 8.2.10.5 Key Personal
      • 8.2.10.6 Analyst View
    • 8.2.11 Parexel International (MA) Corporation
      • 8.2.11.1 Overview
      • 8.2.11.2 Top Products/Service Portfolio
      • 8.2.11.3 Top Competitors
      • 8.2.11.4 Target Customers
      • 8.2.11.5 Key Personal
      • 8.2.11.6 Analyst View
    • 8.2.12 Boehringer Ingelheim International GmbH
      • 8.2.12.1 Overview
      • 8.2.12.2 Top Products/Service Portfolio
      • 8.2.12.3 Top Competitors
      • 8.2.12.4 Target Customers
      • 8.2.12.5 Key Personal
      • 8.2.12.6 Analyst View
    • 8.2.13 Thermo Fisher Scientific, Inc.
      • 8.2.13.1 Overview
      • 8.2.13.2 Top Products/Service Portfolio
      • 8.2.13.3 Top Competitors
      • 8.2.13.4 Target Customers
      • 8.2.13.5 Key Personal
      • 8.2.13.6 Analyst View
    • 8.2.14 Avid Bioservices, Inc.
      • 8.2.14.1 Overview
      • 8.2.14.2 Top Products/Service Portfolio
      • 8.2.14.3 Top Competitors
      • 8.2.14.4 Target Customers
      • 8.2.14.5 Key Personal
      • 8.2.14.6 Analyst View
    • 8.2.15 Novartis AG
      • 8.2.15.1 Overview
      • 8.2.15.2 Top Products/Service Portfolio
      • 8.2.15.3 Top Competitors
      • 8.2.15.4 Target Customers
      • 8.2.15.5 Key Personal
      • 8.2.15.6 Analyst View
    • 8.2.16 List of Emerging Players

9 Research Methodology

  • 9.1 Data Sources
    • 9.1.1 Primary Data Sources
    • 9.1.2 Secondary Data Sources
    • 9.1.3 Data Triangulation
  • 9.2 Market Estimation and Forecast

List of Figures

  • Figure 1: Global Biologics CDMO Market (by Scenario), $Billion, 2024, 2029, and 2035
  • Figure 2: Global Biologics CDMO Market, 2024 and 2035 , $Million
  • Figure 3: Top Countries, Global Biologics CDMO Market, $Million, 2024
  • Figure 4: Biologics CDMO Market, $Million, 2024 and 2035
  • Figure 5: Biologics CDMO Market (by Scale), $Million, 2024, 2030, and 2035
  • Figure 6: Biologics CDMO Market (by Cell Type), $Million, 2024, 2030, and 2035
  • Figure 7: Biologics CDMO Market (by Indication), $Million, 2024, 2030, and 2035
  • Figure 8: Biologics CDMO Market (by Molecule Type), $Million, 2024, 2030, and 2035
  • Figure 9: Biologics CDMO Market (by Service), $Million, 2024, 2030, and 2035
  • Figure 10: Global Biologics CDMO Market, $Million, 2024-2035
  • Figure 11: Number of Patents Filed (by Country), January 2022 to 11th December 2025
  • Figure 12: Number of Patents Filed (by Year), January 2022 to 11th December 2025
  • Figure 13: Incidence of Cancer (by Region), Million, 2020-2040
  • Figure 14: Global Biologics CDMO Market (by Scale), $Million, 2025, 2029, and 2035
  • Figure 15: Global Biologics CDMO Market (Pre-Clinical and Clinical), $Million, 2024-2035
  • Figure 16: Global Biologics CDMO Market (Commercial), $Million, 2024-2035
  • Figure 17: Global Biologics CDMO Market (by Cell Type), $Million, 2025, 2029, and 2035
  • Figure 18: Global Biologics CDMO Market (Mammalian), $Million, 2024-2035
  • Figure 19: Global Biologics CDMO Market (Microbial), $Million, 2024-2035
  • Figure 20: Global Biologics CDMO Market (Others), $Million, 2024-2035
  • Figure 21: Global Biologics CDMO Market (by Indication), $Million, 2025, 2029, and 2035
  • Figure 22: Global Biologics CDMO Market (Oncology), $Million, 2024-2035
  • Figure 23: Global Biologics CDMO Market (Autoimmune Diseases), $Million, 2024-2035
  • Figure 24: Global Biologics CDMO Market (Infectious Diseases), $Million, 2024-2035
  • Figure 25: Global Biologics CDMO Market (Neurology), $Million, 2024-2035
  • Figure 26: Global Biologics CDMO Market (Others), $Million, 2024-2035
  • Figure 27: Global Biologics CDMO Market (by Molecule Type), $Million, 2025, 2029, and 2035
  • Figure 28: Global Biologics CDMO Market (Monoclonal Antibodies), $Million, 2024-2035
  • Figure 29: Global Biologics CDMO Market (Recombinant Proteins), $Million, 2024-2035
  • Figure 30: Global Biologics CDMO Market (Vaccines), $Million, 2024-2035
  • Figure 31: Global Biologics CDMO Market (Hormones), $Million, 2024-2035
  • Figure 32: Global Biologics CDMO Market (Others), $Million, 2024-2035
  • Figure 33: Global Biologics CDMO Market (by Services), $Million, 2025, 2029, and 2035
  • Figure 34: Global Biologics CDMO Market (Cell Line Development), $Million, 2024-2035
  • Figure 35: Global Biologics CDMO Market (Analytical and Formulation Development), $Million, 2024-2035
  • Figure 36: Global Biologics CDMO Market (Process Development), $Million, 2024-2035
  • Figure 37: Global Biologics CDMO Market (cGMP Manufacturing), $Million, 2024-2035
  • Figure 38: Global Biologics CDMO Market (Fill Finish and Packaging), $Million, 2024-2035
  • Figure 39: Global Biologics CDMO Market (Other Services), $Million, 2024-2035
  • Figure 40: North America Biologics CDMO Market, $Million, 2024-2035
  • Figure 41: U.S. Biologics CDMO Market, $Million, 2024-2035
  • Figure 42: Canada Biologics CDMO Market, $Million, 2024-2035
  • Figure 43: Europe Biologics CDMO Market, $Million, 2024-2035
  • Figure 44: Germany Biologics CDMO Market, $Million, 2024-2035
  • Figure 45: U.K. Biologics CDMO Market, $Million, 2024-2035
  • Figure 46: France Biologics CDMO Market, $Million, 2024-2035
  • Figure 47: Italy Biologics CDMO Market, $Million, 2024-2035
  • Figure 48: Spain Biologics CDMO Market, $Million, 2024-2035
  • Figure 49: Rest-of-Europe Biologics CDMO Market, $Million, 2024-2035
  • Figure 50: Asia-Pacific Biologics CDMO Market, $Million, 2024-2035
  • Figure 51: China Biologics CDMO Market, $Million, 2024-2035
  • Figure 52: Japan Biologics CDMO Market, $Million, 2024-2035
  • Figure 53: India Biologics CDMO Market, $Million, 2024-2035
  • Figure 54: South Korea Biologics CDMO Market, $Million, 2024-2035
  • Figure 55: Australia Biologics CDMO Market, $Million, 2024-2035
  • Figure 56: Rest-of-Asia-Pacific Biologics CDMO Market, $Million, 2024-2035
  • Figure 57: Latin America Biologics CDMO Market, $Million, 2024-2035
  • Figure 58: Brazil Biologics CDMO Market, $Million, 2024-2035
  • Figure 59: Mexico Biologics CDMO Market, $Million, 2024-2035
  • Figure 60: Rest-of-Latin America Biologics CDMO Market, $Million, 2024-2035
  • Figure 61: Middle East and Africa Biologics CDMO Market, $Million, 2024-2035
  • Figure 62: K.S.A Biologics CDMO Market, $Million, 2024-2035
  • Figure 63: UAE Biologics CDMO Market, $Million, 2024-2035
  • Figure 64: Rest-of-Middle East and Africa Biologics CDMO Market, $Million, 2024-2035
  • Figure 65: Company Share Analysis, 2023 and 2024
  • Figure 66: Data Triangulation
  • Figure 67: Top-Down and Bottom-Up Approach
  • Figure 68: Assumptions and Limitations

List of Tables

  • Table 1: Market Snapshot
  • Table 2: Global Biologics CDMO Market, Key Market Trends
  • Table 3: Key Recent Developments in Complex Modalities
  • Table 4: Key Developments in Single-Use, Continuous, and Perfusion Bioprocessing in Commercial Manufacturing
  • Table 5: Biologics CDMO Market Regulatory Landscape
  • Table 6: Market Dynamics
  • Table 7: Key Investment and Funding in the Global Biologics CDMO Market
  • Table 8: Key Partnerships and Collaborations in the Global Biologics CDMO Market
  • Table 9: Global Biologics CDMO Market (by Region), $Million, 2024-2035
  • Table 10: North America Biologics CDMO Market (by Cell Type), $Million, 2024-2035
  • Table 11: North America Biologics CDMO Market (by Molecule Type), $Million, 2024-2035
  • Table 12: North America Biologics CDMO Market (by Scale), $Million, 2024-2035
  • Table 13: North America Biologics CDMO Market (by Country), $Million, 2024-2035
  • Table 14: U.S. Biologics CDMO Market (by Cell Type), $Million, 2024-2035
  • Table 15: U.S. Biologics CDMO Market (by Molecule Type), $Million, 2024-2035
  • Table 16: U.S. Biologics CDMO Market (by Scale), $Million, 2024-2035
  • Table 17: Canada Biologics CDMO Market (by Cell Type), $Million, 2024-2035
  • Table 18: Canada Biologics CDMO Market (by Molecule Type), $Million, 2024-2035
  • Table 19: Canada Biologics CDMO Market (by Scale), $Million, 2024-2035
  • Table 20: Europe Biologics CDMO Market (by Cell Type), $Million, 2024-2035
  • Table 21: Europe Biologics CDMO Market (by Molecule Type), $Million, 2024-2035
  • Table 22: Europe Biologics CDMO Market (by Scale), $Million, 2024-2035
  • Table 23: Europe Biologics CDMO Market (by Country), $Million, 2024-2035
  • Table 24: Germany Biologics CDMO Market (by Cell Type), $Million, 2024-2035
  • Table 25: Germany Biologics CDMO Market (by Molecule Type), $Million, 2024-2035
  • Table 26: Germany Biologics CDMO Market (by Scale), $Million, 2024-2035
  • Table 27: U.K. Biologics CDMO Market (by Cell Type), $Million, 2024-2035
  • Table 28: U.K. Biologics CDMO Market (by Molecule Type), $Million, 2024-2035
  • Table 29: U.K. Biologics CDMO Market (by Scale), $Million, 2024-2035
  • Table 30: France Biologics CDMO Market (by Cell Type), $Million, 2024-2035
  • Table 31: France Biologics CDMO Market (by Molecule Type), $Million, 2024-2035
  • Table 32: France Biologics CDMO Market (by Scale), $Million, 2024-2035
  • Table 33: Italy Biologics CDMO Market (by Cell Type), $Million, 2024-2035
  • Table 34: Italy Biologics CDMO Market (by Molecule Type), $Million, 2024-2035
  • Table 35: Italy Biologics CDMO Market (by Scale), $Million, 2024-2035
  • Table 36: Spain Biologics CDMO Market (by Cell Type), $Million, 2024-2035
  • Table 37: Spain Biologics CDMO Market (by Molecule Type), $Million, 2024-2035
  • Table 38: Spain Biologics CDMO Market (by Scale), $Million, 2024-2035
  • Table 39: Rest-of-Europe Biologics CDMO Market (by Cell Type), $Million, 2024-2035
  • Table 40: Rest-of-Europe Biologics CDMO Market (by Molecule Type), $Million, 2024-2035
  • Table 41: Rest-of-Europe Biologics CDMO Market (by Scale), $Million, 2024-2035
  • Table 42: Asia-Pacific Biologics CDMO Market (by Cell Type), $Million, 2024-2035
  • Table 43: Asia-Pacific Biologics CDMO Market (by Molecule Type), $Million, 2024-2035
  • Table 44: Asia-Pacific Biologics CDMO Market (by Scale), $Million, 2024-2035
  • Table 45: Asia-Pacific Biologics CDMO Market (by Country), $Million, 2024-2035
  • Table 46: China Biologics CDMO Market (by Cell Type), $Million, 2024-2035
  • Table 47: China. Biologics CDMO Market (by Molecule Type), $Million, 2024-2035
  • Table 48: China Biologics CDMO Market (by Scale), $Million, 2024-2035
  • Table 49: Japan Biologics CDMO Market (by Cell Type), $Million, 2024-2035
  • Table 50: Japan Biologics CDMO Market (by Molecule Type), $Million, 2024-2035
  • Table 51: Japan Biologics CDMO Market (by Scale), $Million, 2024-2035
  • Table 52: India Biologics CDMO Market (by Cell Type), $Million, 2024-2035
  • Table 53: India Biologics CDMO Market (by Molecule Type), $Million, 2024-2035
  • Table 54: India Biologics CDMO Market (by Scale), $Million, 2024-2035
  • Table 55: South Korea Biologics CDMO Market (by Cell Type), $Million, 2024-2035
  • Table 56: South Korea Biologics CDMO Market (by Molecule Type), $Million, 2024-2035
  • Table 57: South Korea Biologics CDMO Market (by Scale), $Million, 2024-2035
  • Table 58: Australia Biologics CDMO Market (by Cell Type), $Million, 2024-2035
  • Table 59: Australia Biologics CDMO Market (by Molecule Type), $Million, 2024-2035
  • Table 60: Australia Biologics CDMO Market (by Scale), $Million, 2024-2035
  • Table 61: Rest-of-Asia-Pacific Biologics CDMO Market (by Cell Type), $Million, 2024-2035
  • Table 62: Rest-of-Asia-Pacific Biologics CDMO Market (by Molecule Type), $Million, 2024-2035
  • Table 63: Rest-of-Asia-Pacific Biologics CDMO Market (by Scale), $Million, 2024-2035
  • Table 64: Latin America Biologics CDMO Market (by Cell Type), $Million, 2024-2035
  • Table 65: Latin America Biologics CDMO Market (by Molecule Type), $Million, 2024-2035
  • Table 66: Latin America Biologics CDMO Market (by Scale), $Million, 2024-2035
  • Table 67: Latin America Biologics CDMO Market (by Country), $Million, 2024-2035
  • Table 68: Brazil Biologics CDMO Market (by Cell Type), $Million, 2024-2035
  • Table 69: Brazil Biologics CDMO Market (by Molecule Type), $Million, 2024-2035
  • Table 70: Brazil Biologics CDMO Market (by Scale), $Million, 2024-2035
  • Table 71: Mexico Biologics CDMO Market (by Cell Type), $Million, 2024-2035
  • Table 72: Mexico Biologics CDMO Market (by Molecule Type), $Million, 2024-2035
  • Table 73: Mexico Biologics CDMO Market (by Scale), $Million, 2024-2035
  • Table 74: Rest-of-Latin America Biologics CDMO Market (by Cell Type), $Million, 2024-2035
  • Table 75: Rest-of-Latin America Biologics CDMO Market (by Molecule Type), $Million, 2024-2035
  • Table 76: Rest-of-Latin America Biologics CDMO Market (by Scale), $Million, 2024-2035
  • Table 77: Middle East and Africa Biologics CDMO Market (by Cell Type), $Million, 2024-2035
  • Table 78: Middle East and Africa Biologics CDMO Market (by Molecule Type), $Million, 2024-2035
  • Table 79: Middle East and Africa Biologics CDMO Market (by Scale), $Million, 2024-2035
  • Table 80: Middle East and Africa ca Biologics CDMO Market (by Country), $Million, 2024-2035
  • Table 81: K.S.A Biologics CDMO Market (by Cell Type), $Million, 2024-2035
  • Table 82: K.S.A Biologics CDMO Market (by Molecule Type), $Million, 2024-2035
  • Table 83: K.S.A Biologics CDMO Market (by Scale), $Million, 2024-2035
  • Table 84: UAE Biologics CDMO Market (by Cell Type), $Million, 2024-2035
  • Table 85: UAE Biologics CDMO Market (by Molecule Type), $Million, 2024-2035
  • Table 86: UAE Biologics CDMO Market (by Scale), $Million, 2024-2035
  • Table 87: Rest-of-Middle East and Africa Biologics CDMO Market (by Cell Type), $Million, 2024-2035
  • Table 88: Rest-of-Middle East and Africa Biologics CDMO Market (by Molecule Type), $Million, 2024-2035
  • Table 89: Rest-of-Middle East and Africa Biologics CDMO Market (by Scale), $Million, 2024-2035
  • Table 90: Some of the Major Key Strategies: Funding Activities, January 2022 - December 2025
  • Table 91: Some of the Major Key Strategies: Mergers and Acquisitions, January 2022 - December 2025
  • Table 92: Some of the Major Key Strategies: Regulatory Approvals and Product Launches, January 2022 - December 2025
  • Table 93: Some of the Major Key Strategies: Partnerships, Collaborations, and Business Expansions, January 2022 - December 2025